drugset / Trial / NCT01026376
An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Expanded access
No longer available
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea · collab
Summary
The purpose of this study is to provide Decitabine to patients with Myelodysplastic syndrome (MDS) of all FAB (French-American-British) subtypes and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups, including both previously treated and untreated patients.
Timeline
- Start
- 2008-06
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 15 mg/m2 | Intravenous |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |